{
  "label": "clinical_signal_03_dx_vaccine_immunogenicity_016",
  "artifact_type": "distractor_episode",
  "artifact_id": "sha256:fd0ed4247b15022ca949cc7c671e2270e2d1239b9982235d8a9c4dce7ae82364",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:b9a5f4498416bfb2148e106e9d25ca838481bb56025a18e16baf31718f4ee4a2"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:00:51.426483",
  "content": "## 2024-06-17 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 128\n- Active: 121\n- Screen Failures Cumulative: 23\n- Withdrawals Cumulative: 7\n- Low Dose: 31\n- Mid Dose: 32\n- High Dose: 32\n- Placebo: 33\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 76.3\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 18.9\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 117.6\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 177.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 118.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 28.1\n- Mid Dose\n  - IgG Titer (GMU) Mean: 115.9\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 27.1\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 189.8\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 270.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 203.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 49.9\n- High Dose\n  - IgG Titer (GMU) Mean: 155.2\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 40.0\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 257.9\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 380.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 267.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 64.4\n- Placebo\n  - IgG Titer (GMU) Mean: 12.0\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 1.8\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 27.3\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 35.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 28.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 10.2\n\n### Injection Site Reactions\n- Pain Percentage: 50.9\n- Erythema Percentage: 25.4\n- Swelling Percentage: 12.2\n- Induration Percentage: 3.7\n- Mean Pain Duration (Hours): 33.0\n\n### Systemic Reactogenicity\n- Fever Percentage: 18.8\n- Fatigue Percentage: 41.0\n- Myalgia Percentage: 26.6\n- Headache Percentage: 27.6\n- Chills Percentage: 6.9\n\n### Safety Labs\n- WBC (K) Mean: 7.6\n- WBC (K) SD: 1.1\n- Lymphocyte Percentage Mean: 34.4\n- Lymphocyte Percentage SD: 6.2\n- Neutrophil Percentage Mean: 61.1\n- Neutrophil Percentage SD: 5.2\n- Platelets (K) Mean: 229\n- Platelets (K) SD: 41\n- CRP (mg/L) Mean: 6.3\n- CRP (mg/L) SD: 0.6\n- Hemoglobin (g/dL) Mean: 14.8\n- Hemoglobin (g/dL) SD: 1.1\n\n### Adverse Events\n- AE ID: VI-AE-1658\n  - Description: Fever\n  - Grade: 2\n  - Relatedness: Possibly Related\n  - Resolved: True\n  - Dose Group: Mid Dose\n- AE ID: VI-AE-1626\n  - Description: Lymphadenopathy\n  - Grade: 1\n  - Relatedness: Possibly Related\n  - Resolved: True\n  - Dose Group: Mid Dose\n\n### Events\n- Vaccine lot VX-825 temperature excursion assessed: within acceptable range\n- Immunology core lab QC report received\n\n### Notes\n- Week 16: Immunogenicity assessments on schedule. 128 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
  "metadata": {
    "episode_type": "distractor",
    "theme": "vaccine_immunogenicity",
    "theme_index": 1,
    "local_index": 16,
    "scope_id": "clinical_signal_03",
    "layer_name": "distractor_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "86d399f4ea18a5663d6624e24cd8b639bcd4c45932ccbdc83c5254419dc5a8df",
      "components": {
        "transform": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
        "inputs": "c06ced136368edaf"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
      "components": {
        "transform_id": "01137a4997b78f86",
        "source": "c42d9c6282d5331f",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}